Health insurance; coverage for speech therapy as a treatment for stuttering.
HB1633 would require certain Virginia health insurers, health services plans, and health maintenance organizations to cover both habilitative and rehabilitative speech therapy when used to treat stuttering. The bill defines those terms and specifies that coverage must apply whether the stuttering is developmental or otherwise, so long as the plan already covers habilitative and rehabilitative services. It also directs that the required coverage cannot be capped by annual visit limits or other maximum benefit limits, cannot be restricted based on the underlying cause of the stuttering, and cannot be made subject to prior authorization, utilization review, or a medical-necessity determination.
The bill applies to individual and group accident and sickness policies, subscription contracts, and health care plans issued, delivered, or renewed in Virginia on or after January 1, 2026. It excludes short-term travel, accident-only, limited, specified-disease, Medicare-related, and certain short-term nonrenewable policies, and includes a contingency clause delaying application if the mandate would trigger state cost-defrayal obligations under federal law. It also amends the Insurance Code’s HMO-related statutory construction section to incorporate the new mandate into the set of provisions applicable to health maintenance organizations.
If enacted, HB1633 would add a new mandated health insurance benefit in Virginia’s insurance code, requiring coverage for speech therapy as a treatment for stuttering in plans that already cover habilitative and rehabilitative services. It would limit insurers’ ability to impose visit caps, annual maximums, prior authorization, or medical-necessity review for this specific treatment, thereby expanding covered services and reducing utilization controls for affected enrollees. The bill would affect insurers, subscription contract providers, and HMOs in the individual and group markets, while excluding certain short-term and government-related coverage types.
The available voting history suggests limited support at the subcommittee level: the measure was recommended to be laid on the table by a 7-0 vote, which generally indicates no recorded opposition in that vote but also no advancement of the bill at that stage. No committee transcript is available, so there is no recorded floor or committee debate to show broader support or criticism. Overall, the bill appears to have been treated cautiously rather than as a consensus priority.
The main points of potential contention are the breadth of the coverage mandate and the restrictions on insurer management tools. Insurers may object to eliminating annual limits, visit caps, prior authorization, and medical-necessity review for stuttering-related speech therapy, since those provisions reduce cost-control mechanisms. Another possible issue is the bill’s interaction with federal law and the contingency clause tied to state cost defrayal obligations, which could complicate implementation. Because the bill was laid on the table in subcommittee, the practical concern may have been cost, mandate scope, or legislative prioritization rather than a recorded substantive disagreement in the available materials.